|
|
|
15.09.26 - 14:03
|
Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to Advance HIV Response in the U.S. (Business Wire)
|
|
|
Ahead of the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare announced it has funded 230 community-based organizations this year to strengthen essential HIV services and help connect people to HIV prevention and care
DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced more than $33 million in U.S. community grants awarded in 2026. These investments support 230 community-based organizations in 110 cities across 36 states and territories, including Puerto Rico, working to ensure that people and communities most disproportionately impacted by HIV have access to the support they need.
The grants, which were awarded as part of ViiV's Positive Action program, are supporting community-driven solutions to address urgent needs and ensure sustained delivery of essential HIV prevention and care services on the frontlines of the HIV response. The funding helps local organizations connect people to care, red...
|
|
|
|
|
|
|
|
|
|
|
11.09.26 - 06:12
|
Ex-Takeda Pharmaceutical Head Hasegawa Dies at 80 (Nippon)
|
|
|
Tokyo, Sept. 11 (Jiji Press)--Yasuchika Hasegawa, former president of Takeda Pharmaceutical Co. and former chairman of the Japan Association of Corporate Executives, or Keizai Doyukai, died at a Tokyo hospital July 3. He was 80. Born in Nagato, Yamaguchi Prefecture, western Japan, he joined the major drugmaker in 1970 after graduating from Waseda University. In 2003, Hasegawa took over t......
|
|
|
|
|
|
|
09.09.26 - 14:33
|
Encoded Therapeutics Raises $275 Million in Series F Financing to Advance ETX101 Through Pivotal Development and Accelerate its Precision Genetic Medicines Neurology Pipeline (Business Wire)
|
|
|
– Co‑led by GV and another healthcare fund, with participation from new and existing investors –
– Funds ETX101 pivotal and expansion studies in Dravet syndrome alongside commercial scale-up of internal GMP manufacturing facility –
– Positions ETX301 for a 2027 IND submission for post-amputation neuroma pain –SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#ETX101--Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced the close of a $275 million financing. The financing was co-led by GV and another healthcare fund, with participation from ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock.
Proceeds will support the pivotal study of ETX101 in infants and young children with SCN1A+ Dravet syndrome, as well as an expansi...
|
|
|
|
|
|
|
07.09.26 - 23:06
|
Sapporo Breweries CSO on Tariffs, Iran War (Bloomberg)
|
|
|
Sapporo Breweries is shifting some production to the US from Canada due to 50% tariffs imposed on beer exports from the country, Chief Strategy Officer Rieko Shofu said. She spoke exclusively with Bloomberg's Shery Ahn on being impacted by tariffs, as well as the Iran war. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
03.09.26 - 06:01
|
Leqembi® subcutaneous formulation approved for initiation treatment in China (Cision)
|
|
|
Stockholm, Sweden, September 3, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the National Medical Products Administration (NMPA) of China has approved the Leqembi subcutaneous autoinjector formulation (Leqembi SC-AI) as an initiation treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (collectively referred to as early AD).
The application was accepted by the NMPA in January 2026 and was subsequently granted Priority Review designation. Launch in China is planned during Eisai's Fiscal Year 2026 which...
|
|
|
|
|
02.09.26 - 11:36
|
Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology (PBR)
|
|
|
The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. Ono Pharmaceutical
The post Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology appeared first on Pharmaceutical Business review....
|
|
|
02.09.26 - 11:36
|
Takeda and Weave Bio collaborate on AI-driven automation in drug development (PBR)
|
|
|
The partnership aims to integrate Weave Bio's AI tools with Takeda's regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of
The post Takeda and Weave Bio collaborate on AI-driven automation in drug development appeared first on Pharmaceutical Business review....
|
|
|
02.09.26 - 11:06
|
What To Expect After Your Doctor Finds a Lung Nodule (PR Newswire)
|
|
|
American Lung Association's campaign, in partnership with Olympus, offers roadmap to help patients gain control over their health with nodule management and early detection CHICAGO, Sept. 2, 2026 /PRNewswire/ -- One of the greatest opportunities to improve lung cancer outcomes is the......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
